While for patients with chronic heart failure with reduced ejection fraction (HFrEF), there are four well‐established substance classes with a class I guideline recommendation1 (i.e. renin–angiotensin–aldosterone system inhibitors [RAASi], beta‐blockers, mineralocorticoid receptor antagonists [MRA], and sodium‐glucose cotransporter‐2 inhibitors [SGLT2i]), pharmacological treatment for chronic heart failure with mildly reduced ejection (HFmrEF) and preserved ejection fraction (HFpEF) is more challenging for clinicians with limited options. The gene discussed is REN; the disease is congestive heart failure.